HIV/SIV Vaccine Database

Introductory Tour



AIM of this database:

To provide quick access to information about the vaccine research using SIV, HIV and SHIV Research in Nonhuman Primates The vaccine database was constructed to have relational structure using SYBASE database and the PERL programming language to allow data to be accessible and searchable on the internet. A set of criteria was used to scan the Pubmed for relevant studies to enter into the database giving the priority to most recently published challenge studies, the journals generally considered as the primary source of information pertaining to HIV and SIV vaccine research in nonhuman primates.

The database contains the following tables for data entry:

•Reference •Summary •Vaccine •Challenge •Adjuvant •Subject Group •Subject Substance (see next page)



A Relational strategy was used is such a way that data are entered into each table as a separate unit and "anchored" to the Subject Substance table Accessing the Database, click the following URL:

http://hiv.lanl.gov/

Choosing the "Vaccine Trials" option will open the Vaccine Database Home Page.



Searching data in the Vaccine Database



There are two ways of accessing the vaccine database

Either using the Search Form

Or with the Cross-Table Form



Search Form



The search results are displayed in a list but details can be obtained using a navigation panel (click on a Trial number to obtain details)



Searching the database:

•Example: A user searching the database for <u>any</u> trials, <u>any</u> vaccines, with or without challenge can simply press the "search" button which is the database default for "any".

•The results can be displayed in "Reference" (or Trials summary or Results) format.

Output

	HIV/SIV Vaccine Trials Data	base	- Micro	oft Internet Expl	orer					lo):					
	File Edit View Favorites	Tools Help													
П	4+Back + -> - 🕥 🔂 🖽	a. + → - @ 2 2 4 @SeachFavotes @Heds @ [] 2# 22 2													
#ddress 🚵 http://hiv-web.lanl.gov/cgi-bis/vaccine/public/master.cgi								- (PG0 L							
	and the			Notation											
		Keep Selected Remove Selected Veev Trails in Previous Database Search Form Hele													
		📴 Display Format Patteronce 💌 Onlay Titlel No. 💌 Bnow 10 Results Per Page 🕼													
	Databases														
	Sequence DB	Sel	Trial	Author	Year	Pubmed	Title								
	Immunology DB	istance DB www.ibitation. 2001 11720972 Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macagues.													
	Publications:	Cafaro A 2001 11282197 Vaccination with DNA containing fat ceding sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and unmetholated CpO motifs protects cynomolgus monkeys upon infection with the sequences and the													
	FAQ Alignments		NHP.3	Sharpe S	2001	11514732	Induction of similan immunodeficiency virus (BIV)-specific CTL in thesus macaques by vaccination with modified vaccinia virus Anka expressing BIV transgenes: influence of pre-existing anti-vector immunity.	e. e. e. e. e. e. e. e. e. e. e. e. e. e							
	Reviews		NHP.4	Waither-Jallow L	2001	11413371	Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaci cynomolgus monkeys.	Constrained and the second and and an annual definition of the second and an annual definition of the second and annual definition of the second annual definition of the							
	Links	Patersen Li 2001 11420125 \$\ X conformational C4 peptide polymer vaccine coupled with like recombinant vector priming is immunogenic but does not pretect age													
	Vaccine Trials DB:	MEP.d Parren PW 2001 11402774 Antibody protects macaques against vaginal challenge with a pathogenic R5 similarihuman immunodeficiency virus at serum levels give complete neutralization in vitro.													
	Results Tabulation		NHP.Z	Letvin NL	2001	11287555	Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing patient human immunodeficiency virus type 1 isolate envelope (a)	a prir	nary						
	(Dena Testy		NHP.8	Mascola JR	2000	10655111	Protection of macaques against vaginal transmission of a pathogenic HN-1/SIV chimeric virus by passive infusion of neutralizing an	fibod	Hes.						
	Vaccine Trials Links: DHHS Vaccine Trials		NHP.9.1	Hel Z	2000	11017146	Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques								
	IAM Human Trials CHI Pipeline Project		NHP.9.2	Radaelli A	2003	12890631	Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a foxfpox-based GN vaccine in long-term slow-progressor macaques infected with GN/mac251.	mac							
							123438738899899988888875								
							Los Alamos								

Reference



Trial Summary

-	ie Edit Vew Povories	Tada	1460	A 22.0	reet Explorer				-	-	-					
-	- ink - + - (3 3 4)	(3)	anth (alFavor	ter Strada Ci	E Re- de cet la	4									
.,	these a term the web her or	nórg f			wanter.cg						-			*	10	i
											-			_	-	
	a stand	Carr			100.00 = 201 9100		Cale on	That Monteer for Details						1.00		
	A DECK					Keep Selected	Fenove Selected	View Trads in Previous Dia	4.61-910			SeachFam	Hela.			
	199						Davids III a	Traible III		5.6			100			
	3 4 2 20				-91	a Distrie-count	1965005 El 076	el merrer 🔤	show	0.0	100	isutis Per Page	197			
	Databases:															
	Resistance DB	Sel	Treat	Group	Type	Result Category	Assessed	Measur ensent	Yes	No De	t Te	st ValueNotes				
	Immunology DB		NEE.1	1	Placebo (Contrat)	Outzome	Post-Challenge: 2wps	Veranvic	2	1	9	And Viral load	product OHIV Hu2			
	Public ations:															
	FAQ			2	Vaccinee (Case)	Cellularresponse	Pre-Challenge: +3weeks	OTL Response				product gag1	I CLIB BM			
	Tutoriais					Outcome	HORE CLIBINGE SHEE	meme		0		100-107 mRN	A copies permiwith	n 2 weeks fi		
	Reviews											toostede cob				
	Links				Vaccinee (Case)	Outcome	Post-Challenge: 2wpc	Viremic	0		- 4	1 105-107 mill 1	initiand product SHIV	Hu2		
	Vaccine Trials DD															
	Home	Set	Trial	Сконр	Турн	Result Category	Assessed	Moasurement	Yes	No Un	1 10	x Value.Notes				
	Results Tabulation		NEP.2	1	Vascinee (Case)	Outcome	Pre-Challenge: 40 vgx	p27 antigenemia	0	3 0	- 3	product p27 m	sir. Ali ne patre			
	00018 18:00						Post-Challenge	infected with challenge	0	3	э	Med Virus cult	ne -			
	Vaccine Trials Links:															
	MVI Human Triats			2	Vaccines (Case)	Oatcome	Peab-Chailenge: 40 wpz	p27 antigenemia	0	1	- 1	product p27				
	Crarigense risten				Manufacture (Canada	Outcome	Real Chatlenge	interied with challenges								
							Post-Chatlenge: 40 wor	e27 antigonemia	0	1	- 1					
				4	Placebo (Contra)	Outzome	Post-Challenge	infected with challenge	1	0	1					
								p27 antigenemia	0	1	1					
				6	Riscato (Control	Outrome	Rost Challenge	interted with challenge								
				_				inclus in courses								
				2	Naive (Control)	Outcome	Post-Challenge	infected with challenge	2	0	2					
		_														
	Close Datal Menus	Set	Treat	Crowp	Type	Result Category	Assessed	Measur coverd	100	NO CM	4 TK	X Value.Notes				
	December 20 March		1000													
		-		-		-										
		Set	Treat	Group	Dygee	Result Category	Assessed	Me anur erreret	Yes	No the	1.14	st Value.Notes				
			in the	10	Vaccinee (Case)	Outome	Post-chatenge	intected with chattenge	2	a	-	animal in this	your was infected.	hated that to hentewing t	nat.	

Results Details

Cross-Table Form

Tabulation Selection Form
Row Selection: Objective
Column Selection: Vaccine Region
Submit
Close This Window

The Cross-Table Form can be used to generate cross-tabulated data, based on two criteria that you can select using the pull-down menus on the form. For example, to see a trend of efficacy of DNA vaccines over time, the user can tabulate the *Vaccine Type* by *Year of Publication*. The output for each search will display as a table containing numbers as shown in the example below. The number in each box is the count of trials in which the row value and column value both occurred. Values greater than 0 are hot links and are shown in blue. Clicking on blue values will display the trials which make up that box. The numbers below in brackets [x/y] give the number of animals protected from infection followed by the number of animals in the trials.

HIV / SIV VACCINE TRIALS DATABASE	Vaccine Immunogen x Vaccine Subtype												
(work in progress)				7/6	6/04	11:3							
Tabulation Selection Form					_		_	_	_				_
Row Selection: Vaccine Immunogen 💌		Vaccine Immunogen	A	в	С	CRF02_AE	D	F	G	Н	JI	κL	
Column Selection: Vaccine Subtype		HIV-1	1	<mark>60</mark> (55/239)	2	1	1	0	0	0	0	0 0	
Submit		HIV-2	0	0	0	0	0	0	0	0	0	0 0	
		SHIV	0	5 p.39	0	0	0	0	0	0	0	0 0	-
Return		SIV	0	19 (27/116)	0	0	0	0	0	0	0	0 0	
Input				0	ut	put							

We encourage users to contact us with suggestions for improvement.

Thank you